IGI Labs Launch Diclofenac Sodium 1.5% Topical Solution
IGI Laboratories announced the launch of Diclofenac Sodium 1.5% Topical Solution, following its final approval from the Food and Drug Administration (FDA).
Diclofenac Sodium Topical Gel is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain from osteoarthritis of the knee. The mechanism of action of diclofenac is similar to that of other nonsteroidal anti-inflammatory drugs. Diclofenac inhibits the enzyme, cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin.
For more information call (856) 697-1441 or visit IGILabs.com.